<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34075589</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.</ArticleTitle><Pagination><StartPage>309</StartPage><EndPage>320</EndPage><MedlinePgn>309-320</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27339</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">We tested safety, tolerability, and target engagement of tocilizumab in amyotrophic lateral sclerosis (ALS) patients.</AbstractText><AbstractText Label="METHODS">Twenty-two participants, whose peripheral blood mononuclear cell (PBMC) gene expression profile reflected high messenger ribonucleic acid (mRNA) expression of inflammatory markers, were randomized 2:1 to three tocilizumab or placebo treatments (weeks 0, 4, and 8; 8&#xa0;mg/kg intravenous). Participants were followed every 4&#xa0;wk in a double-blind fashion for 16&#x2009;wk and assessed for safety, tolerability, plasma inflammatory markers, and clinical measures. Cerebrospinal fluid (CSF) was collected at baseline and after the third treatment. Participants were genotyped for Asp<sup>358</sup> Ala polymorphism of the interleukin 6 receptor (IL-6R) gene.</AbstractText><AbstractText Label="RESULTS">Baseline characteristics, safety, and tolerability were similar between treatment groups. One serious adverse event was reported in the placebo group; no deaths occurred. Mean plasma C-reactive protein (CRP) level decreased by 88% in the tocilizumab group and increased by 4% in the placebo group (-3.0-fold relative change, P&#x2009;&lt;&#x2009;.001). CSF CRP reduction (-1.8-fold relative change, P&#xa0;=&#xa0;.01) was associated with IL-6R C allele count. No differences in PBMC gene expression or clinical measures were observed between groups.</AbstractText><AbstractText Label="DISCUSSION">Tocilizumab treatment was safe and well tolerated. PBMC gene expression profile was inadequate as a predictive or pharmacodynamic biomarker. Treatment reduced CRP levels in plasma and CSF, with CSF effects potentially dependent on IL-6R Asp<sup>358</sup> Ala genotype. IL-6 trans-signaling may mediate a distinct central nervous system response in individuals inheriting the IL-6R C allele. These results warrant further study in ALS patients where IL-6R genotype and CRP levels may be useful enrichment biomarkers.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milligan</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Anatomy, Wake Forest University, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kansas University, Kansas City, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caress</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest University, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evora</LastName><ForeName>Armineuza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Center for Precision Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wosiski-Kuhn</LastName><ForeName>Marlena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Anatomy, Wake Forest University, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Biostatistics Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS and Neuromuscular Disease Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8574-5332</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neurobiology, Gregory W. Fulton ALS and Neuromuscular Disease Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gregory W. Fulton ALS and Neuromuscular Disease Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02469896</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">interleukin-6</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34075589</ArticleId><ArticleId IdType="mid">NIHMS1723321</ArticleId><ArticleId IdType="pmc">PMC9132344</ArticleId><ArticleId IdType="doi">10.1002/mus.27339</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goetz CG. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve. Mar 2000;23(3):336&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679709</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. Oct 5 2006;52(1):39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. Jan 2019;59(1):10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann J. Results of treatment of certain diseases of the central nervous system with ACTH and corticosteroids. Acta Neurol Scand Suppl. 1965;13 Pt 2:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">4284452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelemen J, Hedlund W, Orlin JB, Berkman EM, Munsat TL. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol. Nov 1983;40(12):752&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">6625990</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Stewart SS, Appel V, et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol. Apr 1988;45(4):381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">3281637</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. Aug 1990;82(2):132&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">2256442</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C. Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials. Front Neurol. 2017-September-25 2017;8(486):486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. Dec 27 2005;65(12):1958&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki MT, Fiala M, Magpantay L, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Robinson M, Strupe J, et al. IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. Nov 2019;6(6):e631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865852</ArticleId><ArticleId IdType="pubmed">31611269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Caress JB, Cartwright MS, Hawkins GA, Milligan C. Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R(358)Ala variant groups in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. May 2021;22(3&#x2013;4):248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">32924606</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, Erta M, Lim SL, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci. Feb 12 2014;34(7):2503&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802757</ArticleId><ArticleId IdType="pubmed">24523541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. Jun 2016;1863(6 Pt A):1218&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">27016501</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MA, Moller JC, Jones LL, Bluethmann H, Kreutzberg GW, Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia. Mar 1997;19(3):227&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">9063729</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. Jun 2011;30(1):4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. Nov 15 2008;112(10):3959&#x2013;3964.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784373</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. Oct 2015;26(5):475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">26189695</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbers C, Monhasery N, Aparicio-Siegmund S, et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim Biophys Acta. Sep 2014;1842(9):1485&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">24878322</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen J, Jansen R, Smit D, et al. The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav Genet. Jul 2014;44(4):368&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283105</ArticleId><ArticleId IdType="pubmed">24791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins GA, Robinson MB, Hastie AT, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol. Aug 2012;130(2):510&#x2013;515 e511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409329</ArticleId><ArticleId IdType="pubmed">22554704</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. Dec 19 2010;3:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018893</ArticleId><ArticleId IdType="pubmed">21234291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Lyon MS, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. Muscle Nerve. Jan 2019;59(1):23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979478</ArticleId></ArticleIdList></Reference><Reference><Citation>Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. Aug 9 2018;132(6):662&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086204</ArticleId><ArticleId IdType="pubmed">29954750</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. May 2018;70:61&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">29499302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. Aug 2016;3(4):e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G, Peter RS, Rosenbohm A, et al. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population- based ALS registry in Germany. Sci Rep. Jun 29 2017;7(1):4374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, et al. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. Jun 1 2017;74(6):660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarov PG, Krylova IB, Evdokimova NR, Nezhinskaya GI, Butyugov AA. C-reactive protein: a pentraxin with anti-acetylcholine activity. Life Sci. May 30 2007;80(24&#x2013;25):2337&#x2013;2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531271</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong T, Nikolaeva M, Acton PJ. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer&#x2019;s disease. Brain Res. Feb 21 1997;749(1):152&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9070642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Liu Z, Wang P, et al. Syncytin-1, an endogenous retroviral protein, triggers the activation of CRP via TLR3 signal cascade in glial cells. Brain Behav Immun. Jan 2018;67:324&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">28928004</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpanini SM, Torvell M, Morgan BP. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. Front Immunol. 2019-March-04 2019;10(362):362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409326</ArticleId><ArticleId IdType="pubmed">30886620</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. Jun 2016;87(6):628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics. Jan 2017;14(1):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>